Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, on Wednesday announced the initiation of a Phase 2 clinical trial for its oral VK2735 tablet formulation, a dual GLP-1/GIP receptor agonist, to treat obesity.
The trial, known as the VENTURE-Oral Dosing Trial, will assess the safety, tolerability, pharmacokinetics, and weight loss efficacy of VK2735, dosed once daily for 13 weeks.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.